When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
While market volume is picking up, there seems to be a visible lack of volatility. Is it a calm before the storm or is it a sign that things are settling down and the rally is for real? Dan Deming, trader at Stutland Equities, and Jeffrey Saut, chief investment strategist at Raymond James, shared their investor insights.
Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.
Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.
One year ago on Sunday September 14, Lehman Brothers was scrambling before declaring bankruptcy later that night and Bank of America announced a deal to acquire Merrill Lynch. Here is a look at where major indices and stocks look one year later.
Look to investing in high quality stocks in this type of market environment, said Donald Yacktman, president and co-CIO of Yacktman Asset Management. He shared his market strategy and stock picks with investors.
The day after President Obama’s impassioned speech for big-government health care, Wall Street bet heavily that the so-called government-insurance option he supports is dead.
Is M&A back on the the rise? The attention grabbing news of potential deals between Disney and Marvel Entertainment last week and now between Kraft Foods and Cadbury might make you think so. Here are what the numbers show:
Merger mania may not be quite in full swing. But the pace of deal-making is showing signs of rousing back to life after nearly a year.
Japan's Daiwa Securities Group plans to buy out Sumitomo Mitsui Financial Group from their investment banking joint venture, a source familiar with the matter said.
G20 policymakers will this weekend promise to keep economic support packages in place until recovery is certain and seek to reassure financial markets they have credible plans to withdraw the stimulus when appropriate.
Chinese technology company Shanda Interactive Entertainment is planning to spin off its video game unit and raise as much as $800 million in a initial public offering in the United States, looking to follow in the footsteps of rival Sohu.com.
Long before the Wall Street crisis, a few agile traders spotted signs that trouble was lurking at Lehman.
Stocks extended their losing streak for a fourth session Wednesday as hardware stocks advanced but worries about the recovery continued to gnaw at the market.
Lost in the coverage of the Pfizer-Wyeth deal that day, but nonetheless disclosed in the company's simultaneous earnings release back on January 26th of this year, PFE revealed it had taken a $2.3 billion charge for a pending settlement over marketing.
Stocks clawed higher Wednesday as tech, insurance and energy stocks advanced. Stocks struggled through the morning after readings on employment and manufacturing came in weaker than expected.
Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.
The list of failed bank continues to grow as the FDIC’s troubled bank list currently stands at 416 troubled banks. Wilbur Ross, chairman and CEO of WL Ross & Co. explained that he expects to see further trouble ahead for banks.
Are there any buying opportunities for investors on the horizon? Jeffrey Saut at Raymond James and Douglas Cliggott at Dover Management shared their market oulooks.
The recession has provided a lot of fodder for comic relief. To help you with your watercooler show, here are more than 50 recession jokes—and some advice for how to tell them. On your mark...get set...joke!